Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FLT3-TKD mutation
i
Other names:
FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2322
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
LeukoStrat® CDx FLT3 Mutation Assay (6)
LeukoStrat® CDx FLT3 Mutation Assay (6)
Associations
(13)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML (NCT05024552)
Phase 1
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Resear...
Recruiting
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Recruiting
Last update posted :
06/13/2024
Initiation :
08/23/2021
Primary completion :
08/01/2024
Completion :
08/01/2025
FLT3
|
FLT3-ITD mutation • FLT3-TKD mutation
|
Xospata (gilteritinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (NCT05554393)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not yet recruiting
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
03/01/2024
Initiation :
05/30/2024
Primary completion :
12/31/2025
Completion :
12/31/2025
TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA
|
TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation • CEBPA mutation
|
Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML (AGORA-1) (NCT05199051)
Phase 2
Centre Antoine Lacassagne
Centre Antoine Lacassagne
Recruiting
Phase 2
Centre Antoine Lacassagne
Recruiting
Last update posted :
11/10/2023
Initiation :
06/03/2023
Primary completion :
03/15/2027
Completion :
03/15/2027
FLT3 • CD33
|
FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive
|
cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) (NCT04027309)
Phase 3
Stichting Hemato-Oncologie voor Volwassenen Nederland
Stichting Hemato-Oncologie voor Volwass...
Active, not recruiting
Phase 3
Stichting Hemato-Oncologie voor Volwassenen Ned...
Active, not recruiting
Last update posted :
06/15/2023
Initiation :
12/20/2019
Primary completion :
12/01/2024
Completion :
06/01/2033
FLT3
|
FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation
|
Xospata (gilteritinib) • Rydapt (midostaurin)
GM-CLAG in Relapsed/Refractory FLT3-mutated AML (NCT05330377)
Phase 1
Ayman H Qasrawi
Ayman H Qasrawi
Withdrawn
Phase 1
Ayman H Qasrawi
Withdrawn
Last update posted :
04/25/2023
Initiation :
03/01/2023
Primary completion :
05/30/2027
Completion :
05/30/2032
FLT3
|
FLT3-ITD mutation • FLT3-TKD mutation
|
cytarabine • Xospata (gilteritinib) • mitoxantrone • cladribine • Neupogen (filgrastim)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login